Last year, the FDA approved dupilumab, the first biologic treatment for atopic dermatitis (AD), and a wave of similar products, now in clinical trials, followed. Biologics provide hope for those suffering from this chronic skin disease, also known as eczema, … Read More
Success of clinical trials is determined after the patient trials are over and the data has been analyzed. In order to eliminate bias and collect quality data which produces meaningful statistics toward study results, it is vital to conduct … Read More
The age of biologics in the treatment of dermatological indications is upon us. They hold promise for dermatological indications where treatments have been sparse. An increased demand for solutions to dermatological conditions where biologics might be effective can be attributed to several factors: increase in incidence of skin cancers, breakthroughs in biologics for psoriasis, and boomer generation demand for anti-aging products.
A History of the Perception of Dermatology In 2011, the American Academy of Dermatology (AAD) conducted a series of interviews using an independent research firm to determine the perception of the dermatology field among the senior leadership of non-dermatological physician … Read More
One third of the world’s population is impacted by dermatologic conditions inclusive of skin, nail and hair disorders. The emergence of biologic therapies for dermatologic conditions created a paradigm shift for these patients, especially those who have not responded well … Read More
Dermatology clinical trials are on the rise, especially in the indications of acne, atopic dermatitis, and psoriatic arthritis.1 Over the course of the past three years, the number of dermatology clinical trials has increased over 40%,2 despite an overall decline … Read More
Many factors can affect the cost and rate of enrollment of a dermatology clinical study. Partnering with a specialty dermatology CRO to offer insights on historical metrics, or create new configurations, can help keep studies on-time and on-budget. In this … Read More
The New Year is off to a swift start here at Novella Clinical following an eventful 2016. Last month was especially exciting as we welcomed a new division through the acquisition of the Phase II-IV Clinical Trials Division (CTD) of … Read More